Regeneron Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGN research report →
About the company
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch).
- CEO
- Leonard S. Schleifer
- IPO
- 1991
- Employees
- 15,158
- HQ
- Tarrytown, NY, US
Price Chart
- Market Cap
- $68.46B
- P/E
- 15.62
- P/S
- 4.59
- P/B
- 2.20
- EV/EBITDA
- 11.87
- Div Yield
- 0.55%
- Gross Margin
- 84.55%
- Op Margin
- 24.32%
- Net Margin
- 29.65%
- ROE
- 14.32%
- ROIC
- 8.53%
- Revenue
- $14.34B · 0.99%
- Net Income
- $4.50B · 2.09%
- EPS
- $43.07 · 5.31%
- Op Income
- $3.58B
- FCF YoY
- 11.35%
- 52W High
- $821.11
- 52W Low
- $541.00
- 50D MA
- $649.16
- 200D MA
- $701.77
- Beta
- 0.24
- Avg Volume
- 1.00M
Get TickerSpark's AI analysis on REGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | RYAN ARTHUR F | sell | 200 |
| May 1, 26 | RYAN ARTHUR F | sell | 5 |
| May 1, 26 | RYAN ARTHUR F | sell | 15 |
| May 1, 26 | RYAN ARTHUR F | sell | 24 |
| May 1, 26 | RYAN ARTHUR F | sell | 15 |
| May 1, 26 | RYAN ARTHUR F | sell | 14 |
| May 1, 26 | RYAN ARTHUR F | sell | 7 |
| May 1, 26 | RYAN ARTHUR F | sell | 4 |
| May 1, 26 | RYAN ARTHUR F | sell | 6 |
| May 1, 26 | RYAN ARTHUR F | sell | 2 |
Our REGN coverage
Recent articles, reports, and earnings notes.
Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Pressure
Regeneron combines a durable cash engine with a broad pipeline, while Dupixent growth and EYLEA HD adoption help offset legacy EYLEA biosimilar pressure. The stock screens as a Buy with valuation still reasonable for a mature biotech compounder.
Talawar Tx SPAC Merger: A Preclinical Biotech Cash-Runway Test
Talawar Tx is a preclinical biotechnology company focused on bispecific antibodies for immunology and inflammatory diseases, and it is going public through a merger with JATT II Acquisition Corp. The deal is expected to close in the second half of 2026, with the setup favoring investors who want exposure to a large-market biotech story but should watch redemption risk and dilution closely.
The market is rotating into cash-flow defensives, not abandoning risk altogether
This week’s move out of semis and into healthcare, financials, staples, and utilities looks more like a demand for earnings visibility than a full-blown risk-off alarm. With payrolls, CPI, ISM data, and early earnings all looming, investors are favoring cash flow and balance-sheet clarity while keeping equity exposure on.
Want a deeper read on REGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.